Article

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Molecular Cancer Therapeutics (Impact Factor: 6.11). 02/2009; 8(2):407-14. DOI: 10.1158/1535-7163.MCT-08-0854
Source: PubMed

ABSTRACT Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.

Download full-text

Full-text

Available from: Nicola J Curtin, Aug 14, 2015
0 Followers
 · 
102 Views
    • "Notwithstanding, sensitization of ABT-888 in combination with temozolomide in xenograft tumour models of glioblastoma seems to have a very limited effect in temozolomideresistant cell lines [176]. The bioavailability of the drug was assessed in a phase 0 clinical trial with 13 patients enrolled with dosage ranging from 10 to 50 mg twice daily. "
    [Show abstract] [Hide abstract]
    ABSTRACT: ADP-ribosylation or PARsylation is one of the most abundant modifications of proteins and DNA. Although the usual context for PARsylation involves the detection and repair of DNA damage in the cell, poly(ADP-ribose) polymerases are known to regulate a number of biological processes besides maintaining genome integrity. One of these processes is the assembly and maintenance of the mitotic spindle where the presence of PARP-1 and tankyrase 1 (TNKS1), two of the best-characterized members of the PARP superfamily, is of critical importance. Here, we recapitulate the biological implications of the absence of poly(ADP-ribose) polymerases and depletion of PARsylation occurrence in mitosis in order to better understand the antimitotic effects of PARP inhibitors. In this regard, we also present an overview of the existing and more relevant molecules, with a special attention to the historical development of their pharmacological properties and structures, as well as a brief summary of clinical trials involving PARP inhibitors.
    Current Topics in Medicinal Chemistry 11/2014; 14(20). DOI:10.2174/1568026614666141130100641 · 3.45 Impact Factor
  • Source
    • ". It is orally bioavailable and crosses the blood—brain barrier. ABT-888 potentiated the cytotoxic effect of temozolomide in several human tumor models and IR in HCT116 human colon cancers [Clarke et al. 2009; Palma et al. 2009; Donawho et al. 2007]. The activity of platinum analogues and cyclophosphamide were also enhanced by ABT-888 in the BRCA1 and 2 defective MX-1 xenografts but ABT-888 had no single-agent activity in this model in the schedule used [Donawho et al. 2007]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi). PARP is involved in single-strand DNA breaks, which in the presence of defective homologous recombination repair lead to double-strand DNA breaks, the most lethal form of DNA damage. These agents therefore may be the drugs of choice for BRCA mutant breast and ovarian cancers. PARPi result in synergistic antitumor effects when combined with cisplatin, temozolomide, topoisomerase inhibitors and ionizing radiation. The indications for PARPi lie beyond BRCA mutations and may include genomic and functional defects in DNA repair and damage response pathways. Several PARPi are in the clinical development phase at this time and, given the recent failure of a phase III clinical trial of iniparib in triple-negative breast cancer, the identification of structural and functional differences between these inhibitors becomes critical. Acquired resistance to PARPi is being noted and represents an important limitation in this field. A concise review of the literature in this field is presented.
    rapeutic Advances in Medical Oncology, The 11/2011; 3(6):257-67. DOI:10.1177/1758834011417039
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes a new TCP variation called Formosa that significantly improves TCP end-to-end performance in terms of high connection throughput and high degree of fairness in resource sharing among multiple competing connections in asymmetric networks. Existing TCP implementations are based on the ACK-clock, which clocks out a single data packet on receipt of an ACK. Formosa TCP pushes the frequency of ACKs per round trip time (RTT) to the lowest limit, using an ACK to cumulatively acknowledge a window's worth of data packets. The congestion window is updated to reflect the available bandwidth estimated on the forward channel, without the aid of the intermediate routers. As a result, the number of ACK packets is significantly reduced, while the principle of “conservation of packets” is still maintained. Based on “an ACK per window,” Formosa estimates forward delay and implements the additive increase and multiplicative decrease algorithm for better congestion avoidance. In addition, it employs the negative acknowledgement mechanism for better congestion control during loss recovery. As compared to existing implementations, TCP Formosa demonstrates the best performance in terms of high connection throughput, high degree of fairness among connections and robustness in the face of two-way transfers in asymmetric networks
    Communications, 2001. ICC 2001. IEEE International Conference on; 02/2001
Show more